Quoin Pharmaceuticals Announces Sponsorship of the FIRST 2024 National Conference

ASHBURN, Va. - Quoin Pharmaceuticals Ltd. (QNRX), a recognized name in the pharmaceutical sector, has officially announced its sponsorship of the forthcoming 2024 National Conference organized by the Foundation for Ichthyosis & Related Skin Types (FIRST). This collaboration underscores Quoin's commitment to supporting communities affected by rare skin disorders and their dedication to advancing healthcare solutions.

Support for Rare Skin Disorder Communities

Through its sponsorship, Quoin Pharmaceuticals amplifies its role in the community by contributing to an essential platform that connects individuals with ichthyosis and related skin types. The FIRST National Conference, set for 2024, offers a unique opportunity for patients, families, clinicians, and researchers to collaborate, share knowledge, and explore new therapeutic strategies.

Advancing Medical Research and Patient Support

By aligning with FIRST's mission, Quoin Pharmaceuticals (QNRX) demonstrates its continued investment in research and development geared towards addressing unmet medical needs within dermatology. This partnership is also indicative of the company's broader goals to support and empower patients, providing them with the resources necessary to live better, healthier lives.

pharmaceuticals, sponsorship, conference